Fennec Pharmaceuticals Inc. (FENC) Stock Price & Analysis

Fennec Pharmaceuticals Inc. (FENC) fell 1.27% to USD 12.39 as of September 8, 2026 at 08:17 UTC, according to Nexqual real-time market data.

FENC last closed at USD 12.39; the session ranged USD 12.29–12.6 on volume of 212,438 shares. Market capitalization is —, with a 52-week range of USD 5.65–13.25 (NCM). Source: Nexqual, September 8, 2026 at 08:17 UTC.

Key Statistics (as of September 8, 2026 at 08:17 UTC)

Technical Analysis (FENC)

Nexqual's technical model rates FENC "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 08:17 UTC.

From Fennec Pharmaceuticals Inc.'s Latest SEC 10-K Filing (filed 2026-03-27)

Key Strengths & Strategy (as disclosed to the SEC)

• If a third party claims that we infringe on their products or technology, we could face a number of issues, including: Third parties may assert that we are employing their proprietary technology without authorization.
• We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information.
• The laws of some foreign countries do not protect our proprietary rights to the same extent or in the same manner as United States laws, and we may encounter significant problems in protecting and defending our proprietary rights in these countries.
• We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies and product are covered by valid and enforceable patents or are effectively maintained as trade secrets.

Partnerships

• On March 16, 2026, Fennec announced that it has entered into an agreement with Cipla Limited and Cipla USA, Inc. to settle the litigation between them regarding Cipla's application to FDA for approval to market a generic version of Fennec's PEDMARK® (sodium thiosulfate injection) product.  See Fennec Pharmaceuticals Inc. v.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 08:17 UTC. This page is informational and not investment advice.